tag:blogger.com,1999:blog-7847433040264752313.post1841052833894627654..comments2015-06-08T04:48:01.242-07:00Comments on ASCO 2015: Noteworthy ASCO findingsBettinahttp://www.blogger.com/profile/02103075738345492061noreply@blogger.comBlogger17125tag:blogger.com,1999:blog-7847433040264752313.post-58924186647937900692015-06-08T04:48:01.242-07:002015-06-08T04:48:01.242-07:00IPILIMUMAB and T-VEC (oncolytic virus) http://abst...IPILIMUMAB and T-VEC (oncolytic virus) http://abstracts.asco.org/156/AbstView_156_151884.html<br />- Overall Response Rate -56% <br />- Complete Responses -33%<br />- Durable Response Rate -44%. <br />- Median progression-free survival (PFS) -10.6 months <br />- Median overall survival (OS) - not reached; <br />- 12-month and 18-month survival- 72.2% and 67%. <br />- 50% of uninjected lesions responded<br />Phase 2 (ipi vs T-VEC+ipi) is ongoing Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-58776313568190775732015-06-08T04:36:21.671-07:002015-06-08T04:36:21.671-07:00This comment has been removed by the author.Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-68848464179063321482015-06-08T03:39:22.704-07:002015-06-08T03:39:22.704-07:00BRAFi ENCO (LGX818) and MEKi BINI (MEK162) -- each...BRAFi ENCO (LGX818) and MEKi BINI (MEK162) -- each shown promising single-agent activity in BRAFV600–mutant melanoma 78 and 72% respectively confirmed RR in phase Ib/II. - http://abstracts.asco.org/156/AbstView_156_146432.html<br />Related -- a Ph III trial Columbus with these agents (US and Europe) https://clinicaltrials.gov/ct2/show/study/NCT01543698#contactsVioleta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-1778844416268678332015-06-04T03:28:12.634-07:002015-06-04T03:28:12.634-07:00Circulating melanoma cells (CMC) is linked with hi...Circulating melanoma cells (CMC) is linked with high risk recurrence in stage III melanoma patients - http://meetinglibrary.asco.org/content/152274-156Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-85390491235105815482015-06-03T06:36:38.698-07:002015-06-03T06:36:38.698-07:00Adjuvant anti-PD-1 clinical trials- http://abstrac...Adjuvant anti-PD-1 clinical trials- http://abstracts.asco.org/156/AbstView_156_151015.html<br />Immune markers suporting the use of anti-PD1 as adjuvant theraphyVioleta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-43112178778417085802015-06-03T05:55:10.235-07:002015-06-03T05:55:10.235-07:00Neoadjuvant BRAF (dabrafenib) and MEK (trametinib)...Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) <br />http://abstracts.asco.org/156/AbstView_156_152525.html<br /><br />Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-69524144516425564702015-06-03T03:23:28.106-07:002015-06-03T03:23:28.106-07:00This comment has been removed by the author.Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-34268565278469883522015-06-02T10:21:16.500-07:002015-06-02T10:21:16.500-07:00TAPUR- a Non Randomized Clinical Trial collecting ...TAPUR- a Non Randomized Clinical Trial collecting real-world data in various cancers http://www.ascopost.com/ViewNews.aspx?nid=28617&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=4210292Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-80557294656180876572015-06-01T15:53:21.629-07:002015-06-01T15:53:21.629-07:00Related to an ASCO presentation - Efficacy of MEK ...Related to an ASCO presentation - Efficacy of MEK Inhibition in Uveal Melanoma http://jama.jamanetwork.com/article.aspx?articleid=1881312<br />on the drug selumetinib vs chemotheraphy in uveal melanoma:<br />- median survival 9.1 months on chemotherapy vs 11.8 months selumetinib<br />- PFS - 7 weeks chemo vs 15.9 weeks selumetinib<br />- OS - no improvement<br />- selumetinib is giving fast responses, good PFS but not improvement in OS.<br />( it can be good as a ''bridge'')<br /><br /><br /><br /><br />Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-51209874228014939192015-06-01T15:36:21.033-07:002015-06-01T15:36:21.033-07:00Linked to this article Modelling vemurafenib resis...Linked to this article Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930354/, a presentation of Dummer ''he recommends cycling through targeted therapies: immunotherapies and then going back on targeted -a more holistic approach.Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-31140201108054654812015-06-01T15:34:36.712-07:002015-06-01T15:34:36.712-07:00This comment has been removed by the author.Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-62167252056871507892015-06-01T15:27:48.176-07:002015-06-01T15:27:48.176-07:00ASCO 2015: Complete Lymph Node Dissection Does Not...ASCO 2015: Complete Lymph Node Dissection Does Not Improve Survival in Patients With Melanoma and Micrometastases - the median follow-up of 35 months shows no significant differences in 3-year and 5-year recurrence-free survival and melanoma-specific survival. http://www.ascopost.com/ViewNews.aspx?nid=28616&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=4210292Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-19057421177988365052015-05-31T14:48:25.215-07:002015-05-31T14:48:25.215-07:00 Clinical characteristics correlated with higher r... Clinical characteristics correlated with higher response to pembrolizumab<br />http://abstracts.asco.org/156/AbstView_156_145183.html<br />-the data are from a phase I trial - 110 patients and ORR = 40%<br />Higher ORR reported when: <br />- LDH ≤ normal (ORR 52.2%), <br />- no previous ipilimumab (ORR 48.3%),<br />- presence of lung metastasis (ORR 52.8%).<br />Patients with liver metastasis had worse response (ORR 18.4%), as did those with liver and lung metastases (ORR 31.3%)Gabrielahttps://www.blogger.com/profile/10322566445879283573noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-26038737730228224142015-05-31T08:52:04.032-07:002015-05-31T08:52:04.032-07:00Dabrafenib +Trametinib vs Dabrafenib (CombiD) - da...Dabrafenib +Trametinib vs Dabrafenib (CombiD) - data from live asco presentation today via Bettina - <br />29% reduction in risk of death combo over monoteraphy<br />25.1 vs 18.7 months PFS in favour of the combo<br />2-year OS- > 50% on combination<br />no data in the abstract http://abstracts.asco.org/156/AbstView_156_149861.html Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-55373863684897308112015-05-31T03:14:21.190-07:002015-05-31T03:14:21.190-07:00http://abstracts.asco.org/156/AbstView_156_152690....http://abstracts.asco.org/156/AbstView_156_152690.html - ...and here is a study (8 cases) on the etiology of uveal melanoma showing that distinctive agents might cause the disease.<br />Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-54630869686816802922015-05-30T16:27:57.541-07:002015-05-30T16:27:57.541-07:00http://abstracts.asco.org/156/AbstView_156_148865....http://abstracts.asco.org/156/AbstView_156_148865.html Here, data from a very small cohort- encouraging use of pembrolizumab for patients with metastatic uveal melanoma. One patient had complete response, one - partial response and one-stable disease. PFS was 12.2 weeks and two patients are still receiving therapy.<br />Violeta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.comtag:blogger.com,1999:blog-7847433040264752313.post-3728240136220198972015-05-30T16:02:17.106-07:002015-05-30T16:02:17.106-07:00Abstract of high interest although not a big surpr...Abstract of high interest although not a big surprise anymore: ipilimumab+ nivolumab almost doubled progression free survival in comparison with ipilimumab alone: 8,9 vs 4,7 months Overall response rate was 60% for combi vs 11% for IPI alone. No complet response was observed in the IPI arm. Also better responses rates on combi - for the patients with poor prognostic factors. http://abstracts.asco.org/156/AbstView_156_144615.htmlVioleta Astratineihttps://www.blogger.com/profile/12687227276797631227noreply@blogger.com